ePlex® Blood Culture Identification Panels
: 24 Jan 2019
Join industry expert Dr. Stefan Juretschko, Director in the Division of Infectious Disease Diagnostics at Northwell Health System for a live webinar on Thursday, January 24, 2019 at 12pm EST (5pm GMT).
Bloodstream infections are a major cause of mortality and morbidity in hospitalized patients. Rapid diagnosis of bloodstream infections is critical to improving the overall clinical outcomes for septic patients. Several molecular methods exist that rapidly detect microorganisms and antimicrobial resistance genes from positive blood cultures or directly from blood. The ePlex Blood Culture Identification (BCID) Panels are novel multiplex assays for the detection of bacterial and fungal organisms and select determinants associated with antimicrobial resistance in positive blood cultures.
The ePlex BCID multiplex PCR panels use a 3-panel design enabling the broadest inclusivity. The BCID-Gram Positive (BCID-GP) Panel identifies 20 gram-positive bacterial targets, 4 resistance genes, Pan Candida and Pan Gram-Negative targets; the BCID-Gram Negative (BCID-GN) Panel identifies 21 gram-negative bacterial targets, 6 resistance genes, Pan Candida and Pan Gram-Positive targets; and, the BCID-Fungal Pathogen (BCID-FP) Panel identifies 11 Candida and 4 additional fungal targets. Broader inclusivity delivers reduced time to result for more organisms, which may improve patient outcome and can enhance antimicrobial stewardship.
For more information or to register for this event, visit The ePlex® Blood Culture Identification Panels: Designed to Improve Patient Care and Clinical Outcome.